Sanofi stock: Q3 sales rise 14.3%, 2026 outlook lifted
Published on 10/30/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSanofi's Q3 growth broadens
- Dupixent and newer medicines led another strong quarter for the French drugmaker.
- Management lifted its full-year sales and business EPS outlook after the latest performance.
- Vaccine revenue declined as respiratory-prevention demand moved through its expected seasonal pattern.
Sanofi reported strong third-quarter results on Friday, October 30, 2026, and raised its full-year outlook. In its Q3 2026 results press release, the French drugmaker reported sales growth of 14.3% at constant exchange rates and business earnings per share growth of 19.6% on the same basis.
Dupixent leads commercial momentum
Dupixent sales increased 34.8% to EUR 5.7 billion, while sales from recent pharmaceutical launches rose 31.4% to EUR 1.4 billion. ALTUVIIIO, Ayvakit and Rezurock were among the products supporting the launch portfolio.
Vaccine sales fell 6.6% to EUR 3.2 billion as respiratory-prevention demand followed its expected phasing. The quarter also included two regulatory approvals, one accepted regulatory submission and two additional designations.
What has changed since our last report
The latest release adds full-quarter net sales of EUR 14.444 billion, IFRS net income of EUR 3.021 billion and free cash flow of EUR 3.269 billion. Business EPS reached EUR 3.55, while IFRS EPS was EUR 2.52; the business figures are non-IFRS measures used by Sanofi to assess operating performance.
Sanofi now expects 2026 sales to grow by a low-teens percentage at constant exchange rates and business EPS to increase by a mid-teens percentage. Management linked the upgrade to commercial momentum, cost discipline and the contribution from newer medicines. The company also highlighted an expanded alliance with Regeneron and further work on its post-Dupixent strategy.
Sanofi stock traded at 79.68 euros on Lang & Schwarz at 16:33 CEST on Friday, October 30, 2026; the real-time quote of Sanofi stock is available here.
Sanofi at a glance
- Company: Sanofi S.A.
- ISIN: FR0000120578
- Reporting period: Third quarter 2026
- Lang & Schwarz quote: 79.68 euros on October 30, 2026, at 16:33 CEST
- 2026 sales outlook: Low-teens percentage growth at constant exchange rates
- 2026 business EPS outlook: Mid-teens percentage growth at constant exchange rates
The Euro Stoxx 50 provides the broader market context for major euro-area companies.
Further product launches, pipeline milestones and progress toward the post-Dupixent strategy will shape the next phase for more news and analyses on Sanofi stock.
